Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31318755 | 0.82 | SRD5A1 (0.47) | SRD5A1MAPTHPGDLMNA | |
| SCHEMBL13039616 | 0.81 | SRD5A1 (0.47) | SRD5A1AKR1C3AKR1C1GAAMAPT | |
| SCHEMBL8920951 | 0.79 | SRD5A1 (0.46) | SRD5A1AKR1C3AKR1C1GAAMAPT | |
| SCHEMBL28243214 | 0.78 | SRD5A1 (0.45) | SRD5A1AKR1C3AKR1C1GAAMAPT | |
| SCHEMBL22321333 | 0.78 | SRD5A1 (0.45) | SRD5A1AKR1C3AKR1C1GAAMAPT | |
| SCHEMBL22048164 | 0.78 | SRD5A1 (0.45) | SRD5A1AKR1C3AKR1C1GAAMAPT | |
| SCHEMBL18585014 | 0.78 | SRD5A1 (0.49) | SRD5A1AKR1C3AKR1C1GAAMAPT | |
| SCHEMBL504750 | 0.76 | TP53 (0.47) | GAALMNA | |
| SCHEMBL6551213 | 0.75 | SRD5A1 (0.46) | SRD5A1AKR1C3AKR1C1GAAMAPT | |
| SCHEMBL3536568 | 0.74 | SRD5A1 (0.45) | SRD5A1AKR1C3AKR1C1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1732906-A4 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-30 | — | — | US | disclosed |
| EP-1753735-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | Transtech Pharma, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1732906-A1 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | disclosed |
| WO-2005103022-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | TRANSTECH PHARMA, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005097767-A1 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-4535081-A | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4423048-A | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor | PFIZER INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4414388-A | ANTIALLERGENS, ANTIULCER AGENTS | PFIZER INC. (US) | 1983-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | BACE2, BACE1, APP | SRD5A1 1500/4885AKR1C3 3257/4885AKR1C1 3081/4885 |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | SRD5A1 836/4885AKR1C3 321/4885AKR1C1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.